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Abstract 24 
Background/Aims: Inflammatory bowel disease (IBD) is accompanied by lesions in 25 
the epithelial barrier, which allow translocation of bacterial products from the gut 26 
lumen to the host’s circulation. IMM-124E is a colostrum-based product, containing 27 
high levels of anti-E.coli-LPS IgG and might limit exposure to bacterial endotoxins. 28 
Here, we investigated whether IMM-124E can ameliorate intestinal inflammation. 29 
Methods: Acute colitis was induced in WT C57Bl/6J mice by administration of 2.5% 30 
DSS for 7 days. T cell transfer colitis was induced via transfer of 0.5x106 naïve T 31 
cells into RAG2-/- C57Bl/6J mice. IMM-124E was administered daily by oral gavage 32 
either preventive or therapeutically.  33 
Results: Treatment with IMM-124E significantly ameliorated colitis in acute DSS 34 
colitis and in T cell transfer colitis. Maximum anti-inflammatory effects were 35 
detected at an IMM-124E concentration of 100 mg/kg body weight, while 25 mg/kg 36 
and 500 mg/kg were less effective. Histology revealed reduced levels of infiltrating 37 
immune cells, and less pronounced mucosal damage. Flow cytometry revealed 38 
reduced numbers of effector T helper cells in the intestine, while levels of regulatory 39 
T cells were enhanced. IMM-124E-treatment reduced the DSS-induced increase of 40 
serum levels of LPS-binding protein, indicating reduced systemic LPS exposure. 41 
Conclusions: Our results demonstrate that oral treatment with IMM-124E 42 
significantly reduces intestinal inflammation, via decreasing the accumulation of 43 
pathogenic T cells, and concomitantly increasing the induction of regulatory T cells. 44 
Our study confirms the therapeutic efficacy of IMM-124E in acute colitis and 45 
suggests that administration of IMM-124E might represent a novel therapeutic 46 
strategy to induce or maintain remission in chronic colitis. 47 
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Introduction 51 
Inflammatory bowel disease (IBD), with its two main sub-forms ulcerative colitis 52 
(UC) and Crohn’s disease (CD), is an important health problem with worldwide 53 
increasing prevalence1, 2. IBD is characterized by chronic and relapsing intestinal 54 
inflammation and affected patients suffer from significant clinical symptoms such as 55 
abdominal pain, diarrhoea or fever3. Extra-intestinal manifestations such as 56 
inflammation of the skin, joints, liver or the eyes are common complications4, 5. 57 
Though the exact pathophysiology is still unknown, it is evident that genetic factors, 58 
environmental triggers, and aberrant immune responses towards the commensal 59 
microbiota contribute to the development of IBD2, 5-7.  60 
 61 
The human intestine is populated by up to 1013 microbes, which form a complex 62 
ecosystem8, 9. While these microbes are usually harmless or even beneficial to the 63 
host10, some microbial products, including the bacterial cell wall component 64 
lipopolysaccharide (LPS), can promote immune responses and thereby contribute to 65 
the development, progression, and exacerbation of IBD11. To prevent translocation of 66 
pro-inflammatory products from the gut lumen to the systemic circulation, where they 67 
elicit strong immune reactions, an adequate protective immunity towards invading 68 
bacteria is crucial. This includes a tight epithelial barrier, as well as rapid clearance of 69 
bacterial products and invading pathogens by innate immune cells located directly 70 
beneath the epithelial layer9, 12. In addition, the production of immunoglobulins (Ig) 71 
against bacterial products prevents those molecules to pass the epithelial surface13, 14. 72 
Further, IgA seems to be involved in determining the composition of the intestinal 73 
microbiome13, 14, which is also a crucial factor for intestinal health8. In IBD, these first 74 
line defence mechanisms are disturbed, and increased levels of bacterial products, 75 
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including LPS are detected in the serum15-17. LPS triggers the activation of toll-like 76 
receptor (TLR)4 on host cells, resulting in production of IL-6, tumour necrosis factor 77 
(TNF), interferon (IFN)-γ, and nitric oxide, which contributes to pro-inflammatory 78 
reactions and exacerbation of the disease15.  79 
 80 
Colostrum is the milk produced by lactating mammals within the first 72 h after 81 
giving birth. In comparison to normal milk, colostrum contains high levels of 82 
immune-active molecules, such as IgA/IgG, growth factors, anti-microbial agents 83 
(e.g. lysozyme and lactoperoxidase), as well as lactoferrin and vitamins18-20. In 84 
contrast to human colostrum, which is rich in IgA, the main immunoglobulin found in 85 
bovine colostrum is IgG. This is of interest, since IgA can pass mucosal surfaces via 86 
the IgA transporter and possibly translocate to the systemic circulation, while IgG 87 
remains in the intestinal lumen. IMM-124E is a bovine colostrum-based product 88 
obtained from cows that have been immunized with LPS from Escherichia coli, 89 
which results in high levels of LPS-specific IgG. A study investigating the 90 
composition of IMM-124E has been published recently, showing that 1mg IMM-91 
124E powder contains about 0.4mg total IgG, which is comparable to the total IgG 92 
content in colostrum powder21. In previous studies, it has been demonstrated that 93 
administration of IMM-124E ameliorates disease in a model of non-alcoholic 94 
steatohepatitis (NASH)22, 23, a disease where chronic presence of LPS and subsequent 95 
low-grade inflammation might promote disease activity24, 25. Further, in TNBS-96 
induced colitis, IMM-124E treatment resulted in reduced colitis severity and 97 
promoted the development of CD4+CD25+ regulatory T cells26, but its effect on 98 
barrier-disruption-mediated colitis has not been addressed so far. In addition, IMM-99 
124E treatment fostered the development of CD25high regulatory T helper and 100 
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regulatory NKT cells in a mouse model of NASH22, indicating that IMM-124E might 101 
have potent immune cell modulatory effects. 102 
Here, we further investigated the anti-inflammatory potential of IMM-124E in two 103 
mouse models of colitis, namely the dextran sodium sulphate (DSS) model of acute 104 
barrier disruption-induced colitis and the naïve T cell transfer model of colitis, to 105 
provide the rationale for its use in IBD patients.  106 
  
7 
7 
Methods 107 
Mice, colitis induction, weight recording, and IMM-124E treatment. All animal 108 
experiments were conducted according to Swiss animal welfare legislation and were 109 
approved by the local animal welfare office (Cantonal veterinary office Zurich; 110 
licence number ZH121/2017). Female C57Bl/6J mice in a weight range between 21 111 
and 23 g were obtained from Janvier Elevages (France) and maintained in a specific 112 
pathogen free (SPF) environment with water and food ad libitum. To induce acute 113 
DSS colitis, mice were randomized into groups with equal average weight and 114 
administered 2.5% dextran sodium sulphate (DSS, MW 36’000-50-000) in the 115 
drinking water for 7 days. RAG2-/- mice on a C57Bl/6J background were initially 116 
obtained from Taconic (Rensselaer, NY), and a local colony maintained in our SPF 117 
facility. To induce T cell transfer colitis, CD4+CD62LhighCD44low naïve T cells were 118 
sorted from the spleen of C57Bl/6J donor mice and 0.5x106 T cells injected per 119 
RAG2-/- recipient. After 4 weeks, mouse endoscopy was performed as described 120 
below, and mice randomized into groups with equal colitis severity prior to start of 121 
treatment. Weight of the mice was recorded daily at the same time. At the last day of 122 
the experiment, colonoscopy (see below) was performed in all animals. Directly after 123 
colonoscopy, blood was collected to obtain serum and mice were sacrificed via 124 
cervical dislocation prior to tissue collection for downstream applications. IMM-124E 125 
and colostrum control powder was provided by Immuron Ltd. (Melbourne, Australia) 126 
and freshly emulsified at an appropriate concentration in autoclaved water directly 127 
prior to administration via oral gavage. The following treatment groups were used in 128 
DSS colitis: preventive treatment: 100 mg/kg body weight or 500 mg/kg IMM-124E 129 
per day, starting two days before beginning of DSS application (day 2 of the 130 
experiment). Administration of 100 mg/kg colostrum from non-immunized cows 131 
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served as a treatment control. Therapeutic treatment: 500 mg/kg IMM-124E per day, 132 
starting at day three of the DSS treatment. In transfer colitis, the following treatment 133 
groups were studied: 25 mg/kg, 100 mg/kg, or 500 mg/kg IMM-124E once per day. 134 
Administration of 100 mg/kg BSA or transfer of regulatory T cells served as controls.  135 
 136 
Mouse endoscopy. To assess macroscopic colitis severity, mice were anesthetised i.p. 137 
with 100 mg/kg body weight ketamine (Vétoquinol, Bern, Switzerland) and 8 mg/kg 138 
body weight Xylazine (Bayer, Lyssach, Switzerland). Animals were examined as 139 
described previously27: recording was performed with the Karl Storz Tele Pack Pal 140 
20043020 (Karl Storz Endoskope, Tuttlingen, Germany), and colitis severity scored 141 
using the murine endoscopic index of colitis severity (MEICS) scoring system as 142 
described previously28 using the following five parameters: (1) transparency of the 143 
colon, (2) changes of the vascular pattern, (3) fibrin visible, (4) granularity of the 144 
mucosal surface and (5) stool consistency. 145 
 146 
Colon length measurement. The entire colon was resected from each mouse and the 147 
length from the cecum to the anus measured prior to dissection to obtain tissue pieces 148 
for downstream applications such as histology, RNA/protein isolation, and MPO 149 
assay. 150 
 151 
Histology. For histological assessment of colitis severity, mice were sacrificed and 152 
1.5cm long pieces from the terminal colon collected and transferred into 4% formalin 153 
solution. After 24h, pieces were dehydrated in ascending alcohol series and 154 
Histoclear® (Chemie Brunschwig, Basel, Switzerland) prior to embedding in 155 
paraffin. The samples were cut into 4um thin sections, transferred onto glass cover 156 
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slides and air-dried. Sections were then rehydrated (incubation in Histoclear®, 157 
followed by descending ethanol series), incubated for 10 min. in Hemalaun solution 158 
(Chemie Brunschwig), rinsed for 10 min. in H2O, incubated for 15 sec. in Eosin 159 
solution (2% w/v; Sigma-Aldrich, Buchs Switzerland), briefly rinsed in H2O, 160 
dehydrated in ascending alcohol series and Histoclear, and finally mounted with 161 
Histopaque embedding solution (Chemie Brunschwig). The extent of colitis was 162 
assessed using the following parameters as described previously29: epithelial damage 163 
(0= normal appearance, 1=partial loss of goblet cells, 2=extended loss of goblet cell, 164 
3=loss of crypt in small areas, 4=extended loss of crypts) and 165 
infiltration/inflammation (0=no infiltration or thickening, 1=infiltration around the 166 
crypt area, 2=infiltration of the mucosa, 3=infiltration of the submucosa, mild 167 
oedema, 4=infiltration reaches the muscularis submucosae, pronounced oedema). 168 
 169 
Myeloperoxidase (MPO) activity assay. Colon specimens were homogenized in 50 170 
mM phosphate buffer (pH 6.0) and 0.5% hexadecyltrimethylammonium bromide 171 
(Sigma-Aldrich) using a gentleMACS tissue homogenizer (Miltenyi Biotech, 172 
Bergisch Gladbach, Germany). After three freeze and thaw cycles, supernatant was 173 
mixed with 0.02% dianisidine (Sigma-Aldrich) in 50 mM phosphate buffer, pH 6.0, 174 
and 0.0005% H2O2 (Sigma-Aldrich). Myeloperoxidase activity, expressed as 175 
arbitrary units, was calculated as mean absorbance (460 nm) per incubation time (in 176 
min) per protein content (in g). 177 
 178 
RNA extraction and RT-PCR. Colon tissue was mechanically dissociated and lysed 179 
in RLT buffer (Qiagen, Venlo, Netherlands) using a GentleMACS tissue homogenizer 180 
(Miltenyi Biotec). Total RNA was isolated from the lysates using RNeasy Mini Kit 181 
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(Qiagen), and DNA removed by TURBO DNA-free Kit (Ambion, Austin, TX) 182 
according to manufacturer's instructions. RNA concentration was assessed by 183 
absorbance at 260 and 280 nm. Complementary DNA (cDNA) synthesis was 184 
performed using a High-Capacity cDNA Reverse Transcription Kit (Applied 185 
Biosystems, Foster City, CA) following the manufacturer’s instructions. Real-time 186 
PCR was performed using FAST qPCR MasterMix for Taqman Assays (Applied 187 
Biosystems) on a Fast HT7900 Real-Time PCR system using SDS Software (Applied 188 
Biosystems) or on a QuantStudio 6 System from Thermo Fisher Scientific (Waltham, 189 
MA). Measurements were performed in triplicates, mouse GAPDH was used as 190 
endogenous control, and results were analyzed by the ΔΔCT method. The real-time 191 
PCR contained an initial enzyme activation step (5 min, 95 °C) followed by 45 cycles 192 
consisting of a denaturing (95 °C, 15 sec) and an annealing/extending (60 °C, 1 min) 193 
step. The used gene expression assays were all obtained from Thermo Fisher 194 
Scientific. 195 
 196 
Protein extraction and Western blot. Colon pieces were disrupted in M-PER buffer 197 
(Thermo fisher Scientific) using a GentleMACS tissue homogenizer. Equal amounts 198 of proteins were loaded on polyacrylamide gels and after separation by gel-199 electrophoresis blotted onto nitrocellulose membranes. Membranes were 200 blocked in a 1% BSA and 3% Milk containing blocking solution, and incubated 201 over night in blocking solution with an appropriate concentration of primary 202 antibody. Membranes were washed three times with washing buffer (Tris 203 buffered saline containing 1% Tween 20 (1%TBST)) before incubation with 204 HRP-coupled anti-rabbit secondary antibody (Lab Force, Santa Cruz, CA) for 2 205 hours. Immunoreactive proteins were detected with a Fusion Solo S imager 206 
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(Vilber Lourmat, Witec AG, Littau, Switzerland) using a Western Blotting 207 detection kit (Western Bright Sirius or ECL, Advansta, Menlo Park, CA). Anti-208 
phospho NF-κB-p65 (Ser536) and anti-NF-κB-p65, antibodies were obtained from 209 
Cell Signaling Technologies (Danvers, MA).  210 
 211 
IgG depletion from IMM-124E. To deplete IgG from IMM-124E, the IMM-124E 212 
suspension was incubated with Sepharose A beads (250 ul beads/ml suspension) for 2 213 
h at room temperature. As control, IMM-124E suspension was incubated with non-214 
protein coupled Sepharose beads for 2 h. The suspensions were then centrifuged at 215 
250 x g for 2 min. and supernatants used for gavages.  216 
 217 
Colon Explants. For colon explants, 1 cm of the colon was opened longitudinally, 218 
rinsed with PBS and cultured for 24 h in 0.5 ml RPMI (Thermo Fisher Scientific) 219 
supplemented with 10% FCS, and 1% Penicillin/Streptomycin solution (Thermo 220 
Fisher Scientific) in an incubator (37°C, 10% CO2). 221 
 222 
Enzyme-linked immunosorbent Assay (ELISA). Cytokine measurement were 223 
performed using commercial ELISA kits from R&D (Minneapolis, MN; IL-6, IL-10, 224 
TNF, IFN-γ) and HycultBiotech (Uden, Netherlands; LBP ELISA). All Assays were 225 
performed according to the manufacturer’s instructions. 226 
 227 
Flow cytometry. Lamina propria immune cells were isolated as described 228 
previously27, 30. In brief, the colon was opened, rinsed in PBS, cut in 0.5cm pieces and 229 
epithelial cells removed by repeated incubation in EDTA-containing HBSS and 230 
rigorous shaking. Tissue pieces were then digested for 15-25 min. in RPMI 231 
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supplemented with 10% FCS, 0.6 mg/ml collagenase IV (Roche, Basel, Switzerland) 232 
and 2.4 mg/ml dispase (Sigma-Aldrich). Remaining tissue was homogenized using a 233 
26G needle and passed over a 40um mesh. For intracellular cytokine staining, cells 234 
were treated with PMA (50 ng/ml, Sigma-Aldrich, Buchs, Switzerland), Ionomycin 235 
(1µg/ml, Sigma-Aldrich) in the presence of 10 ng/ml Brefeldin A (Sigma-Aldrich) for 236 
3 h. Cells were harvested, washed in PBS, stained for surface molecules for 30 min., 237 
washed in FACS buffer (PBS, 2% FCS), and fixed in fixation/permeabilization buffer 238 
(BD, Franklin Lakes, NJ) for 15 min. Cells were washed and resuspended in 239 
permeabilization buffer (BD) prior to addition of anti-IFN-γ and anti-IL-17 antibody 240 
for 15 min. Before analysis, cells were washed in permeabilization buffer and 241 
resuspended in FACS buffer. A LSR Fortessa analyzer from BD was used for all 242 
analysis. 243 
 244 
LPS measurement in mouse serum. HEKblue-mTLR4 cells (Invivogen) were 245 
cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FCS and 246 
2mM L-glutamine. For LPS detection, 20ul serum was added to 96 well plates and 247 
200’000 HEKblue-mTLR4 cells in 180ul HEK-Blue detection medium (Invivogen) 248 
were added per well. After 24 h, absorbance at 630 nm was measured and 249 
concentrations calculated based on a standard curve prepared from pure LPS diluted 250 
in mouse serum. 251 
    252 
Statistics. Unless otherwise stated, data are presented as means ± standard error of the 253 
mean (SEM) for one out of two independent experiments. n equals the number of 254 
mice in one experiment. Statistical analysis was performed by analysis of variance 255 
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(ANOVA) followed by Mann-Whitney U and Bonferroni correction was used to 256 
correct for multiple testing. P values < 0.05 were considered significant.  257 
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Results 258 
Administration of IMM-124E prevents acute DSS-induced colitis. 259 
To test whether administration of IMM-124E is able to ameliorate colitis in vivo, we 260 
induced acute colitis in WT C57Bl/6J mice via administration of 2.5% DSS in the 261 
drinking water for 7 days. This treatment resulted in severe intestinal inflammation, 262 
characterized by diarrhoea, severe weight loss (Figure 1A), macroscopic signs of 263 
colitis in endoscopy accompanied by elevated MEICS score (colon wall thickening, 264 
disturbed vascularization pattern, granular appearance of the colon wall, fibrin 265 
deposits, and loose stool, Figure 1B+C), shortening of the colon (Figure 1D), 266 
increased levels of myeloperoxidase in colon tissue (Figure 1E), and histological 267 
signs of severe colitis (erosion of the epithelium, infiltration of immune cells, edema 268 
in the sub-epithelium; figure 1F-I). 269 
To test whether IMM-124E prevents colitis development, mice were treated with 100 270 
mg/kg body weight or 500 mg/kg IMM-124E per day, starting two days before 271 
beginning of DSS application (preventive treatment). Administration of 100 mg/kg 272 
colostrum from non-immunized cows served as a treatment control. Another group 273 
received 500 mg/kg IMM-124E in a therapeutic setting, starting the gavages at day 274 
three of the DSS treatment. Of interest, all treatment schedules resulted in less severe 275 
weight loss in comparison to DSS only (Figure 1A), while colon length was not 276 
changed in any of the treatment groups (Figure 1D). However, other indicators of 277 
colitis severity showed clear differences between the treatment groups: for instance, 278 
MPO levels were only reduced in mice treated with 100 mg/kg IMM-124E, while 500 279 
mg/kg IMM-124E (preventive or therapeutic) and colostrum administration did not 280 
affect MPO activity (Figure 1E). Preventive treatment with IMM-124E (100 mg/kg 281 
and 500 mg/kg) or with colostrum resulted in less severe colitis, as observed in mouse 282 
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endoscopy, while therapeutic treatment did not significantly reduce macroscopic signs 283 
of colitis (Figure 1B+C). Preventive 100 mg/kg IMM-124E treatment had the most 284 
pronounced effect, which was most overt in reduced levels of disturbed 285 
vascularization and granularity of the colon wall. Histological assessment of the 286 
terminal colon revealed that preventive treatment with 100 mg/kg IMM-124E 287 
significantly reduced epithelial damage and, albeit not statistically significant 288 
(p=0.06), infiltration of immune cells into the submucosal layer, resulting in a 289 
reduction of total histology score (Figure 1F-I). Of note, none of the other treatments 290 
did result in a significant reduction of histological parameters of colitis. This clearly 291 
indicates that IMM-124E treatment prevents DSS-induced colitis, and that treatment 292 
with 100 mg/kg IMM-124E is most effective.   293 
 294 
IMM-124E reduces pro-inflammatory cytokine production 295 
To understand the molecular mechanisms how IMM-124E reduced the extent of 296 
colitis in the acute DSS model, we next studied mRNA expression of pro- and anti-297 
inflammatory cytokines in colon tissue from DSS-treated mice that received IMM-298 
124E either preventive (100 mg/kg and 500 mg/kg) or therapeutically (500 mg/kg). 299 
Of note, DSS-treatment resulted in enhanced expression of Il6, Il10, Ifng and Tnfa. 300 
While preventive IMM-124E and colostrum administration inhibited the increase in 301 
Il6 and Il10 mRNA expression (Figures 2A+B), elevated Ifng and Tnfa expression 302 
was still present (Figure 2C+D). In line with increased mRNA expression upon DSS-303 
administration, IL-6, IFN-γ and TNF cytokine levels in the supernatant of colon 304 
explants from DSS-treated mice were also elevated (Figure 2E-H). Of interest, 305 
cytokine levels of IL-6, IFN-γ and TNF were significantly reduced in the supernatant 306 
of colon explants from mice that received 100 mg/kg IMM-124E, while preventive 307 
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treatment with 500 mg/kg IMM-124E resulted in decreased IL-6 and IFN-γ levels 308 
only and treatment with 100 mg/kg colostrum had no effect on the secretion of these 309 
cytokines (Figure 2E, G+H). IL-10 levels were not significantly affected by any of the 310 
treatments (Figure 2F). 311 
 312 
IMM-124E ameliorates T cell mediated colitis. 313 
DSS-treatment results in erosion of the epithelial layer, and thus represents important 314 
features that contribute to colitis onset in IBD patients. However, it only partially 315 
reflects the involvement of immune cells in the pathogenesis of intestinal 316 
inflammation. In particular, the effect of pathogenic T cell responses is not reflected 317 
in this model31. Therefore, we next investigated the effect of IMM-124E treatment in 318 
the T cell transfer model of colitis, where naïve T cells are transferred into B- and T-319 
cell deficient recipients. As expected, T cell transfer resulted in first signs of colitis 320 
after three weeks, characterized by onset of diarrhoea and macroscopic signs of colon 321 
inflammation in mouse endoscopy (Figure 3A). Upon onset of colitis, mice were 322 
randomized into groups with equal colitis severity and treated with 25 mg/kg, 100 323 
mg/kg, or 500 mg/kg IMM-124E once per day. Since colostrum itself contains high 324 
levels of IgG and other factors that might act as confounders, administration of 100 325 
mg/kg BSA or transfer of regulatory T cells served as controls. Although weight 326 
development did not differ significantly between the treatment groups (not shown), 327 
colonoscopy revealed that colitis was clearly reduced in mice receiving 100 mg/kg 328 
IMM-124E two weeks after the start of IMM-124E treatment (Figure 3B), an 329 
observation that was confirmed by assessment of spleen weight, colon length, and 330 
histology scores (Figure 3C-F).  331 
 332 
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IMM-124E affects immune cells in the inflamed colon. 333 
It has previously been shown that IMM-124E treatment results in enhanced levels of 334 
CD4+CD25+ regulatory T cells in a TNBS-mediated colitis model as well as in NASH 335 
patients22, 23. To address whether IMM-124E treatment also affects CD4+ T cells in 336 
the transfer colitis model, we performed flow cytometry on mesenteric lymph nodes 337 
(mLN) and colonic lamina propria lymphocytes (LPL). Flow cytometry revealed that 338 
administration of IMM-124E resulted in reduced levels of Th effector cells in mLN 339 
and LPL. In particular, proportions of CD4+ IFN-γ + Th1, IL-17+ Th17, and IL-13+ 340 
Th2 cells were reduced (Figure 4A-C), while the proportion of FoxP3+ regulatory T 341 
cells was enhanced in the colonic lamina propria and mLN of mice treated with 100 342 
mg/kg IMM-124E (Figure 4D). While 25 mg/kg and 500 mg/kg IMM-124E treatment 343 
had some effect on Th cell subsets, this was clearly less pronounced. On the other 344 
hand, numbers of NK1.1+ NK cells were very low and no significant effects were 345 
observed upon colitis induction or IMM-124E treatment (Figure 4E). Of note, all the 346 
beneficial effects observed upon IMM-124E treatment were absent in the control 347 
group receiving BSA. 348 
 349 
IMM-124E prevents systemic LPS exposure upon colitis induction. 350 
IMM-124E contains high levels of anti-LPS IgG, and might therefore neutralize LPS 351 
translocation from the gut lumen into the systemic circulation. Although LPS itself is 352 
typically below detection limits, systemic exposure to LPS results in expression of 353 
LPS-binding protein (LBP), and LBP levels correlate with the extent of LPS 354 
exposure. Therefore, we next addressed whether LBP levels are increased in DSS 355 
colitis, and whether IMM-124E administration might affect LBP levels in the serum 356 
of DSS treated mice. In line with a severe barrier defect, DSS-treatment resulted in 357 
  
18 
18 
significantly enhanced serum levels of LBP (Figure 5A). IMM-124E administration 358 
significantly reduced serum levels of LBP. However, and in contrast to a better 359 
response to 100 mg/kg IMM-124E with respect to colitis indicators, this effect was 360 
not dose-dependent, i.e. 500 mg/kg IMM-124E administration was as effective as 100 361 
mg/kg, while administration of colostrum did not affect serum LBP levels (Figure 362 
5A). Nevertheless, levels of LBP moderately correlated with histological scores 363 
(Figure 5B), indicating that systemic LPS translocation might be involved in 364 
mediating disease in DSS-induced colitis. LBP serum levels were also increased in T 365 
cell transfer colitis (Figure 5C), however to a lesser extent than in the DSS model. 366 
Again, IMM-124E administration reduced LBP levels in the serum, but there was 367 
only a weak correlation between LBP levels and total histology scores (Figure 5D). 368 
To investigate whether there is direct presence of LPS in the mouse serum after colitis 369 
induction, we next used HEKble-mTLR4 cells. These cells carry a reporter for 370 
mouseTLR4 activation. When HEKble-mTLR4 cells were incubated with serum from 371 
control mice, there was no TLR4 activation detectable. DSS-treatment in contrast 372 
resulted in TLR4 activation, indicating presence of LPS in those mice. In line with 373 
reduced LBP serum levels, TLR4 activation was lower in cells incubated with serum 374 
from IMM-124E-treated mice. Again, the 100mg/kg IMM-124E was the most 375 
effective dose (Figure 5E). To further investigate whether IMM-124E treatment 376 
reduces LPS-induced signalling cascades in DSS-treated mice, we analysed activation 377 
of NF-κB in colon lysates from mice with acute colitis with or without IMM-124E 378 
treatment. We saw a strong induction of NF-κB p65 phosphorylation in DSS-treated 379 
mice, which was clearly suppressed upon treatment with IMM-124E (Figure 5F). To 380 
address whether IMM-124E treatment also results in reduced translocation of whole 381 
bacteria, we measured levels of bacterial 16S rDNA in mesenteric lymph nodes from 382 
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our mice. However, we only observed 16S rDNA in very few mice, and did not 383 
observe any clear pattern (data not shown). Taken together, these data indicate that 384 
IMM-124E-treatment prevents DSS-induced systemic exposure to LPS and LPS-385 
induced pro-inflammatory signalling. 386 
 387 
Therapeutic potential of IMM-124E is partially dependent on presence of IgG. 388 
To further investigate the mechanism of action of IMM-124E, we next performed an 389 
acute DSS colitis experiment using either the normal IMM-124E preparation, or IgG-390 
depleted IMM-124E. In line with our findings that IMM-124E-treatment reduces 391 
exposure to LPS, which is likely due to high levels of anti-LPS antibody load, IgG 392 
depletion from IMM-124E partially abrogated the beneficial effect of IMM-124E 393 
(Figure 6).   394 
 395 
 396 
  397 
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Discussion 398 
In this study, we demonstrated that administration of IMM-124E ameliorates colitis in 399 
two mechanistically different mouse models of intestinal inflammation, namely the 400 
DSS model of epithelial injury, and the immune-cell mediated T cell transfer colitis. 401 
IMM-124E administration significantly reduced DSS-mediated induction of pro-402 
inflammatory cytokines in the intestine, including IL6 and TNF. In T cell transfer 403 
colitis, IMM-124E administration reduced levels of Th1, Th2, and Th17 cells, but 404 
promoted the induction of regulatory T cells. Further, IMM-124E significantly 405 
reduced systemic LPS exposure/presence of LPS in the serum. 406 
 407 
Of interest, the most effective dose of IMM-124E administration was 100mg/kg, 408 
which was even more effective than higher doses of IMM-124.  Since the exact 409 
mechanism how Imm-124E works is still elusive, it is hard to tell why this might be 410 
the case. One possible explanation could be that high doses of IMM-124E might 411 
result in the formation of immune complexes of IgG with LPS, which could activate 412 
antigen-presenting cells in the intestine and thus promote pro-inflammatory effects. 413 
On the other hand, IMM-124E is a cow milk based product. Adult mice do not usually 414 
ingest milk and in combination with a barrier defect exposure to high levels of milk 415 
proteins might contribute to disease symptoms and thus suppress the beneficial effect 416 
of IMM-124E. However, further experiments would be required to understand the 417 
exact mechanism why IMM-124E is most effective at 100mg/kg.  418 
 419 
A recent study that investigated how IMM-124E might exert its anti-diarrheagenic 420 
effects, demonstrated that IMM-124E has direct anti-bacterial activity via inhibition 421 
of growth and migration of bacteria21. This indicates that also during colitis, the 422 
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beneficial effect of IMM-124E is possibly due to direct anti-bacterial properties, 423 
which might lead to decreased translocation of invading pathogens. However, we only 424 
observed 16S rDNA transcripts in mesenteric lymph nodes from very few DSS-425 
treated mice. Additional experiments would be required to assess whether direct anti-426 
microbial properties of IMM-124E play a role in protecting from colitis,. 427 
 428 
It has previously been demonstrated that IMM-124E administration ameliorates 429 
insulin resistance and alleviates liver injury in a mouse model of NASH22, an effect 430 
associated with alteration in regulatory T cell and NKT cell proportions. In a small, 431 
open-label trial with 10 NASH patients, IMM-124E administration alleviated insulin 432 
resistance and improved lipid profile, which was accompanied by increased levels of 433 
regulatory T cells23. It has further been demonstrated that IMM-124E alleviates 434 
immune-mediated colitis in the TNBS model26. Also in this model, IMM-124E 435 
treatment resulted in elevated levels of regulatory T cells, and serum levels of IL-10 436 
were significantly enhanced26. While we also found significantly elevated levels of 437 
CD4+FoxP3+ regulatory T cells in the transfer colitis model, we did not see an effect 438 
on NK cells, possibly because the abundance of these cells is rather low in mLN and 439 
the lamina propria, and their abundance might be generally altered in RAG2-/- 440 
recipients due to absence of T- B- and NKT cells.  441 
 442 
In colitis, altered cytokine responses significantly contribute to disease development 443 
and exacerbation32. IL-10 is one of the most important anti-inflammatory cytokines 444 
for the maintenance of intestinal health33-35, and defects in the IL-10 signalling 445 
pathway predisposes to very early onset of IBD36, 37. While Ya’acov et al found 446 
increased levels of IL-10 in the serum of TNBS treated mice that received IMM-447 
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124E26, we found that IMM-124E prevented DSS-induced induction of IL10 mRNA 448 
expression, and there was no significant effect on IL-10 secretion. This indicates that 449 
in the DSS model, the effect of IMM-124E does not seem to be mediated via effects 450 
on the regulatory cytokine IL-10. In NASH patients treated with IMM-124E, an 451 
increase in IL-6 serum levels was observed23. However, in the DSS model, we 452 
observed an induction of IL-6 upon DSS-treatment, which was reduced in IMM-124E 453 
treated mice. This might be due to different modes of action, i.e. the role of IL-6 in 454 
NASH remains controversial, with studies showing that blocking of IL-6 promotes 455 
disease38 and activation of IL-6 signalling alleviated disease in a NASH model39, 456 
whereas anti-IL6 treatment improved barrier function in DSS colitis40 and ameliorated 457 
disease in T cell transfer colitis41 458 
 459 
T helper cells play a major role in the development and progression of IBD42, and 460 
several studies demonstrated enhanced levels of IFN-γ+ Th1 and IL-17+ Th17 cells, 461 
while relative numbers of regulatory T cells are decreased (reviewed in43). IMM-124E 462 
administration corrected the altered balance in Th cells in the transfer colitis models, 463 
via reduction of exacerbated Th cell responses, and concomitant enhanced induction 464 
of regulatory T cells. This clearly demonstrates that IMM-124E administration 465 
reduces aberrant Th cell activation during colitis, and has the ability to promote anti-466 
inflammatory responses. 467 
 468 
NK cells and NKT cells are unique subsets of immune cells that produce large 469 
amounts of IFN-γ and TNF upon activation. Further, they exert cytotoxic functions 470 
and lyse aberrant cells, including tumour cells44. Adar et al described increased levels 471 
of NK and NKT cells in IMM-124E treated ob/ob mice22. However, we could not 472 
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determine any difference in NK cell numbers in mesenteric lymph nodes or the 473 
lamina propria of IMM-124E treated mice. Of note, NKT cells are absent in RAG2-/- 474 
mice, and cannot be studied in this model. The differences in NK cell induction 475 
between our study and the stud from Adar et al might further be explained by the fact 476 
that NK cells exert different effects depending on the disease context44. In 477 
experimental models of NASH, injection of NK cells alleviated disease via regulation 478 
of macrophage activation45, 46, while studies of NK cell numbers in IBD have yielded 479 
conflicting results47, 48.   480 
 481 
Especially in the DSS colitis model, innate immune cells, including cells of the 482 
myeloid lineage, such as macrophages and granulocytes, are important drivers of 483 
disease31 and there is evidence that these cells also play crucial roles in the onset of 484 
IBD in humans49, 50. While we did not address immune cells in detail in the DSS 485 
model, we measured MPO levels, which are a good indicator of myeloid cell 486 
infiltration and function51. In line with decreased levels of infiltrating immune cells 487 
into the inflamed colon of IMM-124E treated mice, MPO levels were also 488 
significantly decreased, indicating that in addition to prevent aberrant induction of Th 489 
cells, IMM-124E also prevents the accumulation of activated myeloid cells. 490 
 491 
Summarized, our results demonstrate that IMM-124E administration significantly 492 
ameliorates experimental colitis and might be a promising novel therapeutic agent in 493 
IBD, either as a stand-alone treatment for maintaining remission in mild colitis cases 494 
or in combination with other treatments to increase therapeutic efficacy and prevent 495 
loss of therapeutic response.  496 
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Figure Legends.  655 
Figure 1. IMM-124E administration prevents acute DSS colitis. Acute colitis was 656 
induced in female C57Bl/6J mice via administration of 2.5% DSS in the drinking 657 
water for seven days (day 2-9 of the experiment). Mice received 100 mg/kg or 500 658 
mg/kg body weight IMM-124E per daily oral gavage starting at day 0 (preventive 659 
treatment) or at day 4 (therapeutic treatment). Depicted are A) weight development, 660 
B) representative pictures from mouse endoscopy and C) respective scoring according 661 
to the of murine endoscopy index of colitis severity (MEICS) score, D) colon length, 662 
E) myeloperoxidase (MPO) activity in the colon, E) representative pictures of H&E 663 
stained terminal colon sections and scoring of F) epithelial damage, G) inflammation, 664 
and H) summarized histological score. Asterisks denote significant differences 665 
(*=p<0.05, **=p<0.01, ***=p<0.001) A+C: n=6 per group, data are represented as 666 
mean ± SEM. D-H: each dot represents one individual mouse, horizontal bars stand 667 
for mean, whiskers indicate SEM.  668 
 669 
Figure 2. IMM-124E prevents DSS-induced elevation of IL-6, IFN-γ and TNF-α. 670 
Acute colitis was induced in female C57Bl/6J mice via administration of 2.5% DSS in 671 
the drinking water for seven days (day 3-9 of the experiment). Mice received 100 672 
mg/kg or 500 mg/kg body weight IMM-124E per daily oral gavage starting at day 1 673 
(preventive treatment) or at day 5 (therapeutic treatment). A-D: mRNA expression 674 
levels of the indicated genes in the terminal colon were analysed by RT-PCR and 675 
normalized to Gapdh and the median of untreated controls. E-H: Colon pieces were 676 
incubated in RPMI for 24 h and levels of the indicated cytokines in the supernatant 677 
analysed by ELISA. Each dot represents an individual mouse, horizontal bars indicate 678 
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mean, and whiskers indicate SEM. Asterisks denote significant differences 679 
(*=p<0.05, **=p<0.01).  680 
 681 
Figure 3. IMM-124E ameliorates T-cell transfer colitis. Colitis was induced in 682 
RAG2-/- mice via transfer of 0.5x106 naïve T cells. Control mice received no T cells 683 
or 0.5x106 naïve T cells + 0.5x106 regulatory T cells. At day 24, colonoscopy was 684 
performed to verify colitis induction, and mice were distributed into groups with 685 
equal colitis severity. Starting at day 24, mice received 25 mg/kg, 100 mg/kg or 500 686 
mg/kg IMM-124E, or 100 mg/kg BSA per daily oral gavage until the end of the 687 
experiment 4 weeks later. Depicted are A) representative pictures from colonoscopy 688 
on day 24, B) representative pictures and scoring according to the murine endoscopic 689 
index of colitis severity (MEICS) score from colonoscopy at the end of the 690 
experiment, C) spleen weight, D) colon length, E) histological scoring and F) 691 
representative pictures of H&E stained sections of the terminal colon. Each dot 692 
represents an individual mouse horizontal bars indicate mean, and whiskers indicate 693 
SEM. n=7 for each group, except control without T cells (n=8) and BSA (n=5). 694 
Asterisks denote significant differences (*=p<0.05, **=p<0.01). 695 
 696 
Figure 4. Altered immune cell subsets upon treatment with IMM-124E. Colitis 697 
was induced in RAG2-/- mice via transfer of 0.5x106 naïve T cells. Control mice 698 
received no T cells or 0.5x106 naïve T cells + 0.5x106 regulatory T cells. At day 24, 699 
colonoscopy was performed to verify colitis induction, and mice were distributed into 700 
groups with equal colitis severity. Starting at day 24, mice received 25 mg/kg, 100 701 
mg/kg or 500 mg/kg IMM-124E, or 100 mg/kg BSA per daily oral gavage until the 702 
end of the experiment 4 weeks later. Immune cells from the mesenteric lymph nodes 703 
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(mLN) or the lamina propria (LPL) were analysed by flow cytometry for A-D) T cells 704 
expressing the indicated cytokines and E) proportion of NK cells. Each dot represents 705 
an individual mouse, horizontal bars indicate mean, and whiskers indicate SEM. 706 
Asterisks denote significant differences (*=p<0.05, **=p<0.01). 707 
 708 
Figure 5. IMM-124E prevents systemic exposure to LPS. A+B) Acute colitis was 709 
induced in female B57BL/6 mice via administration of 2.5% DSS in the drinking 710 
water for seven days (day 3-9 of the experiment). Mice received 100 mg/kg or 500 711 
mg/kg body weight IMM-124E per daily oral gavage starting at day 1 (preventive 712 
treatment) or at day 5 (therapeutic treatment). Serum was collected at the end of the 713 
experiment and analysed for the concentration of LPS-binding protein (LBP) by 714 
ELISA (A) and LBP levels were correlated to total histology scores from the same 715 
mice (B). n=6 per group. C+D) Colitis was induced in RAG2-/- mice via transfer of 716 
0.5x106 naïve T cells. Control mice received no T cells or 0.5x106 naïve T cells + 717 
0.5x106 regulatory T cells. At day 24, colonoscopy was performed to verify colitis 718 
induction, and mice were distributed into groups with equal colitis severity. Starting 719 
at day 24, mice received 25 mg/kg, 100 mg/kg or 500 mg/kg IMM-124E, or 100 720 
mg/kg BSA per daily oral gavage until the end of the experiment 4 weeks later. 721 
Serum was collected at the end of the experiment and analysed for the concentration 722 
of LPS-binding protein (LBP) by ELISA (C) and LBP values correlated with total 723 
histology scores from the same mice (D). n=7 in each group, except no T cells control 724 
(n=8) and BSA treated (n=5) group. E) Serum from mice in A (acute DSS colitis) and 725 
C (T cells transfer colitis) was incubated with HEKblue-mTLR4 reporter cells for 48h 726 
to determine presence of LPS. SEAP activity levels were measured at 620nm and 727 
correspond to the amount of LPS present in the serum. F) Representative pictures and 728 
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respective densitometric analysis of colon lysates from mice treated as in A (acute 729 
colitis). n=3 for each treatment condition. Each dot represents an individual mouse, 730 
horizontal bars indicate mean, and whiskers indicate SEM. Asterisks denote 731 
significant differences (*=p<0.05, **=p<0.01). In B+D the line indicates the best-fit.  732 
 733 
Figure 6. Depletion of IgG from IMM-124E partially abrogates its beneficial 734 
effect. Acute colitis was induced in female C57Bl/6J mice via administration of 2.5% 735 
DSS in the drinking water for seven days (day 2-9 of the experiment). Mice received 736 
100 mg/kg body weight normal IMM-124E, or IgG-depleted IMM-124E per daily 737 
oral gavage starting at day 0. Depicted are A) weight development, B) representative 738 
pictures from mouse endoscopy and C) respective scoring according to the of murine 739 
endoscopy index of colitis severity (MEICS) score, D) colon length, E) representative 740 
pictures of H&E stained terminal colon sections, and F) histological scoring. 741 
Asterisks denote significant differences (*=p<0.05, **=p<0.01, ***=p<0.001) n=5 742 
per group, data are represented as mean ± SEM, and each dot represents one 743 
individual mouse, horizontal bars stand for mean, whiskers indicate SEM. 744 
